For the quarter ended December 2023, Boston Scientific (BSX - Free Report) reported revenue of $3.73 billion, up 14.9% over the same period last year. EPS came in at $0.55, compared to $0.45 in the year-ago quarter.
The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $3.59 billion. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Cardiovascular- Interventional Cardiology Therapies- United States: $188 million versus $176.49 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.8% change.
- Geographic Revenue- U.S. $2.21 billion versus $2.13 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.4% change.
- Net Sales- Cardiovascular- Peripheral Interventions- United States: $292 million versus $282.94 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change.
- Net Sales- Cardiovascular- Peripheral Interventions- International: $242 million compared to the $248.69 million average estimate based on four analysts. The reported number represents a change of +15.2% year over year.
- Net Sales- MedSurg- Worldwide: $1.44 billion versus $1.40 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.
- Net Sales- Cardiovascular- Worldwide: $2.29 billion versus $2.19 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +14% change.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $1.75 billion compared to the $1.66 billion average estimate based on seven analysts. The reported number represents a change of +14.5% year over year.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $533 million versus $529.05 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +12% change.
- Net Sales- MedSurg- Endoscopy- Worldwide: $645 million versus $637.11 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +13% change.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $269 million versus $257.49 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8% change.
- Net Sales- MedSurg- Urology- Worldwide: $527 million compared to the $506.68 million average estimate based on seven analysts. The reported number represents a change of +10.5% year over year.
- Net Sales- Cardiovascular- Interventional Cardiology Therapies- Worldwide: $614 million versus $584.77 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
View all Key Company Metrics for Boston Scientific here>>>Shares of Boston Scientific have returned +6.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
For the quarter ended December 2023, Boston Scientific (BSX - Free Report) reported revenue of $3.73 billion, up 14.9% over the same period last year. EPS came in at $0.55, compared to $0.45 in the year-ago quarter.
The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $3.59 billion. With the consensus EPS estimate being $0.51, the EPS surprise was +7.84%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Cardiovascular- Interventional Cardiology Therapies- United States: $188 million versus $176.49 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.8% change.
- Geographic Revenue- U.S. $2.21 billion versus $2.13 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.4% change.
- Net Sales- Cardiovascular- Peripheral Interventions- United States: $292 million versus $282.94 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +9.8% change.
- Net Sales- Cardiovascular- Peripheral Interventions- International: $242 million compared to the $248.69 million average estimate based on four analysts. The reported number represents a change of +15.2% year over year.
- Net Sales- MedSurg- Worldwide: $1.44 billion versus $1.40 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.
- Net Sales- Cardiovascular- Worldwide: $2.29 billion versus $2.19 billion estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +14% change.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $1.75 billion compared to the $1.66 billion average estimate based on seven analysts. The reported number represents a change of +14.5% year over year.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $533 million versus $529.05 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +12% change.
- Net Sales- MedSurg- Endoscopy- Worldwide: $645 million versus $637.11 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +13% change.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $269 million versus $257.49 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8% change.
- Net Sales- MedSurg- Urology- Worldwide: $527 million compared to the $506.68 million average estimate based on seven analysts. The reported number represents a change of +10.5% year over year.
- Net Sales- Cardiovascular- Interventional Cardiology Therapies- Worldwide: $614 million versus $584.77 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.
View all Key Company Metrics for Boston Scientific here>>>Shares of Boston Scientific have returned +6.2% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on BSX - FREE